Zydus Lifesciences’ Baddi Facility Cleared by USFDA with VAI Classification

Zydus Lifesciences announced that its Baddi manufacturing facility has successfully cleared a recent inspection by the U.S. Food and Drug Administration (USFDA). Conducted between August 4 and August 13, 2025, the inspection resulted in the issuance of an Establishment Inspection Report (EIR), officially closing the review process. The facility was classified under the Voluntary Action Indicated (VAI) category, which means that while some issues may have been noted, they do not warrant regulatory action and can be addressed voluntarily by the company.

This development strengthens Zydus Lifesciences’ position in the U.S. pharmaceutical market and reinforces its commitment to maintaining high-quality manufacturing standards. The Baddi site plays a key role in the company’s global supply chain, and the positive outcome of the inspection is expected to support future product approvals and exports.

Key highlights and major takeaways

• USFDA inspection conducted from August 4–13, 2025  
• Baddi facility receives Establishment Inspection Report (EIR)  
• Classification: Voluntary Action Indicated (VAI)  
• No regulatory action required; issues to be resolved voluntarily  
• Inspection officially closed by USFDA  
• Boosts Zydus’ credibility in U.S. and global markets  

Sources: ScanX News, InvestyWise, Economic Times Pharma